CY1122604T1 - Αγγειοτασινη ii σε συνδυασμο για την αντιμετωπιση υποτασης - Google Patents
Αγγειοτασινη ii σε συνδυασμο για την αντιμετωπιση υποτασηςInfo
- Publication number
- CY1122604T1 CY1122604T1 CY20201100026T CY201100026T CY1122604T1 CY 1122604 T1 CY1122604 T1 CY 1122604T1 CY 20201100026 T CY20201100026 T CY 20201100026T CY 201100026 T CY201100026 T CY 201100026T CY 1122604 T1 CY1122604 T1 CY 1122604T1
- Authority
- CY
- Cyprus
- Prior art keywords
- mcg
- dose
- equivalent
- angiotasin
- hypotension
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/085—Angiotensins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361917576P | 2013-12-18 | 2013-12-18 | |
| US201461955706P | 2014-03-19 | 2014-03-19 | |
| PCT/US2014/071186 WO2015095535A1 (en) | 2013-12-18 | 2014-12-18 | Angiotensin ii alone or in combination for the treatment of hypotension |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1122604T1 true CY1122604T1 (el) | 2021-03-12 |
Family
ID=53367119
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20201100026T CY1122604T1 (el) | 2013-12-18 | 2020-01-13 | Αγγειοτασινη ii σε συνδυασμο για την αντιμετωπιση υποτασης |
Country Status (23)
| Country | Link |
|---|---|
| US (7) | US9220745B2 (pt-PT) |
| EP (2) | EP2986308B1 (pt-PT) |
| JP (3) | JP6824739B2 (pt-PT) |
| KR (3) | KR20220028125A (pt-PT) |
| CN (3) | CN112546197A (pt-PT) |
| AU (2) | AU2014364528C1 (pt-PT) |
| BR (1) | BR112016013961A2 (pt-PT) |
| CA (1) | CA2933601A1 (pt-PT) |
| CY (1) | CY1122604T1 (pt-PT) |
| DK (1) | DK2986308T3 (pt-PT) |
| EA (1) | EA037823B1 (pt-PT) |
| ES (1) | ES2771749T3 (pt-PT) |
| HR (1) | HRP20200009T1 (pt-PT) |
| HU (1) | HUE047062T2 (pt-PT) |
| IL (1) | IL246162B (pt-PT) |
| LT (1) | LT2986308T (pt-PT) |
| MX (2) | MX2016008108A (pt-PT) |
| NZ (1) | NZ721089A (pt-PT) |
| PL (1) | PL2986308T3 (pt-PT) |
| PT (1) | PT2986308T (pt-PT) |
| RS (1) | RS59804B1 (pt-PT) |
| SI (1) | SI2986308T1 (pt-PT) |
| WO (1) | WO2015095535A1 (pt-PT) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9572856B2 (en) | 2009-12-16 | 2017-02-21 | The George Washington University a Congressionally Chartered Not-for-Profit Corporation | Method of treating low blood pressure |
| JP6824739B2 (ja) | 2013-12-18 | 2021-02-03 | ザ ジョージ ワシントン ユニヴァーシティ、ア コングレッショナル チャータード ノット−フォー−プロフィット コーポレーション | 低血圧治療のための単独または併用使用されるアンギオテンシンｉｉ |
| BR112017000303A2 (pt) * | 2014-07-08 | 2017-11-07 | La Jolla Pharma Co | métodos para o tratamento de hipotensão |
| US9919022B2 (en) | 2015-03-20 | 2018-03-20 | Arthur J. ATKINSON, JR. | Use of angiotensin II (AII) receptor agonists to prevent or reduce hemodialysis-associated skeletal muscle cramps |
| US20170196931A1 (en) * | 2016-01-07 | 2017-07-13 | Lakhmir Chawla | Methods of Administering Vasopressors |
| WO2017120438A1 (en) * | 2016-01-07 | 2017-07-13 | La Jolla Pharmaceutical Company | Methods for administering angiotensin ii |
| US11583568B2 (en) | 2017-04-14 | 2023-02-21 | La Jolla Pharma, Llc | Methods for administering angiotensin II |
| WO2019118874A1 (en) * | 2017-12-15 | 2019-06-20 | La Jolla Pharma, Llc | Angiotensin compositions and methods related thereto |
| WO2023244552A1 (en) * | 2022-06-15 | 2023-12-21 | Virginia Commonwealth University | Methods for fluid resuscitation of an organ donor |
| WO2024129057A1 (en) * | 2022-12-12 | 2024-06-20 | Proletariat Therapeutics, Inc. | Methods of treating cardiac injury |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU181008B (en) | 1980-01-18 | 1983-05-30 | Richter Gedeon Vegyeszet | Process for producing angiotenzin-ii analogues of antagonistic activity containing sarcosyl-group at the 1-positon,and an alpha-hydroxy-carboxylic acid at the 8-position |
| US5216025A (en) | 1989-09-13 | 1993-06-01 | Board Of Regents, The University Of Texas System | Nitric oxide synthesis inhibitors for potentiating the action of pressor agents in certain hypotensive patients |
| US5444067A (en) | 1993-08-30 | 1995-08-22 | Merck & Co., Inc. | Pharmaceutical treatment methods using angiotensin II receptor agonists bearing a thiophene moiety |
| CA2448051A1 (en) | 2001-06-04 | 2002-12-12 | Human Genome Sciences, Inc. | Methods and compositions for modulating ace-2 activity |
| US7115266B2 (en) | 2001-10-05 | 2006-10-03 | Cytos Biotechnology Ag | Angiotensin peptide-carrier conjugates and uses thereof |
| WO2005044313A2 (en) | 2003-11-06 | 2005-05-19 | Amersham Health As | Conjugates of angiotensin ii and an imaging moiety |
| NO20034952D0 (no) | 2003-11-06 | 2003-11-06 | Amersham Health As | Farmasöytiske forbindelser |
| FR2880807B1 (fr) * | 2005-01-19 | 2007-04-13 | Aguettant Sa Lab | Composition pharmaceutique injectable |
| JP2009510056A (ja) | 2005-09-29 | 2009-03-12 | ファイブローゲン、インコーポレーテッド | 血圧を低下させる方法 |
| US20090304818A1 (en) | 2005-12-30 | 2009-12-10 | May Clive N | Method of treatment |
| EP2029137A2 (en) | 2006-06-15 | 2009-03-04 | Gilead Colorado, Inc. | Antihypertensive therapy method |
| WO2008130217A1 (en) * | 2006-08-08 | 2008-10-30 | Applied Nanosystems B.V. | Cyclic angiotensin analogs |
| BRPI0719319A2 (pt) | 2006-11-17 | 2014-02-04 | Da Volterra | Liberação colônica usando contas de zn/pectina com um revestimento de eudragit |
| WO2009009907A1 (en) * | 2007-07-18 | 2009-01-22 | The University Of British Columbia | Use of vasopressin-receptor agonists for the treatment of septic shock |
| EP2161030A1 (en) * | 2008-09-09 | 2010-03-10 | Rijksuniversiteit te Groningen | Oxytocin formulations and uses thereof |
| NZ592644A (en) | 2008-11-28 | 2013-09-27 | Abbott Lab | Stable antibody compositions and methods for stabilizing same |
| US9572856B2 (en) | 2009-12-16 | 2017-02-21 | The George Washington University a Congressionally Chartered Not-for-Profit Corporation | Method of treating low blood pressure |
| FR2959414B1 (fr) * | 2010-04-30 | 2016-01-08 | Luc Quintin | Combinaison de molecules aux fins de traitement d'hypotension survenant au cours du choc septique, cardiogenique, ou anaphylactique refractaire, ou hemorragique terminal, apres correction de la volemie et de l'etat de mal asthmatique refractaire |
| WO2012009545A1 (en) | 2010-07-14 | 2012-01-19 | Cumberland Emerging Technologies, Inc | Methods of treating hepatorenal syndrome and hepatic encephalopathy with thromboxane-a2 receptor antagonists |
| JP6522584B2 (ja) | 2013-04-26 | 2019-05-29 | ラ ホヤ ファーマシューティカル カンパニーＬａ Ｊｏｌｌａ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏｍｐａｎｙ | 腎不全を処置するための組成物及び方法 |
| JP6824739B2 (ja) | 2013-12-18 | 2021-02-03 | ザ ジョージ ワシントン ユニヴァーシティ、ア コングレッショナル チャータード ノット−フォー−プロフィット コーポレーション | 低血圧治療のための単独または併用使用されるアンギオテンシンｉｉ |
| US20150286797A1 (en) | 2014-04-02 | 2015-10-08 | David R. Ratto | System and method for administering medication |
| BR112017000303A2 (pt) * | 2014-07-08 | 2017-11-07 | La Jolla Pharma Co | métodos para o tratamento de hipotensão |
| WO2017120438A1 (en) | 2016-01-07 | 2017-07-13 | La Jolla Pharmaceutical Company | Methods for administering angiotensin ii |
| US20170196931A1 (en) | 2016-01-07 | 2017-07-13 | Lakhmir Chawla | Methods of Administering Vasopressors |
| US11583568B2 (en) | 2017-04-14 | 2023-02-21 | La Jolla Pharma, Llc | Methods for administering angiotensin II |
| WO2019118874A1 (en) | 2017-12-15 | 2019-06-20 | La Jolla Pharma, Llc | Angiotensin compositions and methods related thereto |
-
2014
- 2014-12-18 JP JP2016539318A patent/JP6824739B2/ja active Active
- 2014-12-18 CN CN202011494632.XA patent/CN112546197A/zh active Pending
- 2014-12-18 WO PCT/US2014/071186 patent/WO2015095535A1/en active Application Filing
- 2014-12-18 CN CN201480075899.1A patent/CN106061493A/zh active Pending
- 2014-12-18 DK DK14872684.7T patent/DK2986308T3/da active
- 2014-12-18 KR KR1020227004084A patent/KR20220028125A/ko active Application Filing
- 2014-12-18 EP EP14872684.7A patent/EP2986308B1/en active Active
- 2014-12-18 BR BR112016013961A patent/BR112016013961A2/pt not_active Application Discontinuation
- 2014-12-18 LT LTEP14872684.7T patent/LT2986308T/lt unknown
- 2014-12-18 NZ NZ721089A patent/NZ721089A/en unknown
- 2014-12-18 EP EP19197866.7A patent/EP3607962A1/en active Pending
- 2014-12-18 PL PL14872684T patent/PL2986308T3/pl unknown
- 2014-12-18 AU AU2014364528A patent/AU2014364528C1/en active Active
- 2014-12-18 PT PT148726847T patent/PT2986308T/pt unknown
- 2014-12-18 ES ES14872684T patent/ES2771749T3/es active Active
- 2014-12-18 KR KR1020237012136A patent/KR20230051721A/ko not_active Application Discontinuation
- 2014-12-18 SI SI201431450T patent/SI2986308T1/sl unknown
- 2014-12-18 RS RS20200021A patent/RS59804B1/sr unknown
- 2014-12-18 EA EA201691258A patent/EA037823B1/ru unknown
- 2014-12-18 MX MX2016008108A patent/MX2016008108A/es unknown
- 2014-12-18 HU HUE14872684A patent/HUE047062T2/hu unknown
- 2014-12-18 CN CN202010824424.5A patent/CN111920939A/zh active Pending
- 2014-12-18 CA CA2933601A patent/CA2933601A1/en active Pending
- 2014-12-18 KR KR1020167019427A patent/KR102399383B1/ko active IP Right Grant
- 2014-12-18 US US14/575,127 patent/US9220745B2/en active Active
-
2015
- 2015-11-13 US US14/941,301 patent/US10028995B2/en active Active
-
2016
- 2016-06-09 IL IL246162A patent/IL246162B/en active IP Right Grant
- 2016-06-17 MX MX2020011190A patent/MX2020011190A/es unknown
-
2018
- 2018-03-01 US US15/909,617 patent/US10493124B2/en active Active
- 2018-09-19 US US16/135,608 patent/US10765722B2/en active Active
-
2019
- 2019-04-12 US US16/382,850 patent/US11096983B2/en active Active
- 2019-08-23 JP JP2019153144A patent/JP7175506B2/ja active Active
-
2020
- 2020-01-03 HR HRP20200009TT patent/HRP20200009T1/hr unknown
- 2020-01-13 CY CY20201100026T patent/CY1122604T1/el unknown
- 2020-11-26 AU AU2020277230A patent/AU2020277230A1/en active Pending
-
2021
- 2021-07-20 US US17/380,311 patent/US11559559B2/en active Active
-
2022
- 2022-07-14 JP JP2022113327A patent/JP2022137224A/ja active Pending
-
2023
- 2023-01-23 US US18/157,933 patent/US20230226141A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1122604T1 (el) | Αγγειοτασινη ii σε συνδυασμο για την αντιμετωπιση υποτασης | |
| CY1124298T1 (el) | Φενφλουραμινη για χρηση στην θεραπευτικη αντιμετωπιση του συνδρομου dravet | |
| CY1123460T1 (el) | Ενωσεις και μεθοδοι για τη θεραπεια μιας επιληπτικης διαταραχης | |
| CY1120506T1 (el) | Θεραπευτικα δραστικες ενωσεις και μεθοδοι χρησης αυτων | |
| CY1122186T1 (el) | Μεθοδοι θεραπειας καρκινου | |
| MX2020001732A (es) | Tratamiento de las afecciones del sistema nervioso central. | |
| MX2018006674A (es) | Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control. | |
| CY1124596T1 (el) | Φαρμακευτικη συνθεση τραμαδολης για οφθαλμικη χρηση | |
| EA201690212A1 (ru) | Способы лечения или профилактики офтальмологических патологических состояний | |
| EA201590703A1 (ru) | Ингибиторы mek при лечении вирусных заболеваний | |
| CY1124759T1 (el) | Μεθοδοι για τη θεραπεια της οξειας νεφρικης βλαβης | |
| CY1120490T1 (el) | Φαρμακο για την προληψη και/ή την θεραπευτικη αντιμετωπιση της πολυκυστικης νοσου των νεφρων | |
| BR112017026061A2 (pt) | composto, uso de um composto, e, método de tratamento de uma infecção viral | |
| EA201691567A1 (ru) | Способы лечения легких травм головного мозга | |
| AR120055A1 (es) | Métodos para tratar la enfermedad de fabry en pacientes que tienen insuficiencia renal | |
| CY1117438T1 (el) | Μεθοδος για την προληψη και την θεραπευτικη αντιμετωπιση της σηψης | |
| EA201991688A1 (ru) | Фармацевтические комбинации для лечения рака | |
| EA201891968A1 (ru) | Комбинированное лечение с использованием liv1-adc и химиотерапевтического средства | |
| EA201892631A1 (ru) | Дигидротестостерон и производные и промоторы дигидротестостерона в лечении рака | |
| MX2016003525A (es) | Agentes dirigidos contra una interaccion cis de molecula de orientacion repulsiva a (rgma) /neogenina o balsas lipidicas y uso de los mismos en metodos de tratamiento. | |
| EA201891008A3 (ru) | Лечение симптомов, связанных с андроген-депривационной терапией | |
| EA202190226A1 (ru) | СПОСОБЫ ЛЕЧЕНИЯ HFpEF С ИСПОЛЬЗОВАНИЕМ ДАПАГЛИФЛОЗИНА И СОДЕРЖАЩИХ ЕГО КОМПОЗИЦИЙ | |
| DOP2014000258A (es) | Tratamiento de la metástasis en el cerebro con una combinación de veliparib y una terapia con radiación en la totalidad del cerebro | |
| EA202090336A1 (ru) | Соединения, их соли и способы лечения заболеваний | |
| EA201890497A3 (ru) | Способ лечения лабильной и пароксизмальной гипертензии |